Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Lung Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Thoracic Neoplasm
Lung Neoplasm

Cancer Family

Lung Neoplasm

CI-CAN-00000221Explore in graph →

Non-malignant2,726 active trials51 approved drugs619 evidence items

NCIt: C3200
MeSH: D008175

Overview
Statistics
Survival
Genomics41
Variants & evidence619
Drugs128
Trials11603
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (483)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 326–350 of 483 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib.
· Front Oncol · 2022 · PMID 36419889 · validated civic_curation pubmed
EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report.
· Lung Cancer · 2018 · PMID 29290255 · validated civic_curation pubmed
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
· Cancer Res · 2010 · PMID 21030459 · validated civic_curation pubmed
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
· Cancer Discov · 2011 · PMID 22328973 · validated civic_curation pubmed
Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC.
· Lung Cancer · 2014 · PMID 24636847 · validated civic_curation pubmed
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
· J Thorac Oncol · 2011 · PMID 21623265 · validated civic_curation pubmed
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
· Cancer Discov · 2015 · PMID 25971939 · validated

Showing 326–350 of 483 publications

← Previous
1
…
13
14
15
…
20
Next →

civic_curation

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

· Lung Cancer · 2012 · PMID 22325357 · validated civic_curation pubmed

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.

· J Clin Oncol · 2016 · PMID 26729443 · validated civic_curation pubmed

Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer.

· J Thorac Oncol · 2015 · PMID 25789838 · validated civic_curation pubmed

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

· Nat Commun · 2016 · PMID 26883990 · validated civic_curation pubmed

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

· Cancer Discov · 2015 · PMID 25971938 · validated civic_curation pubmed

Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.

· Clin Cancer Res · 2015 · PMID 25688157 · validated civic_curation pubmed

Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.

· Anticancer Drugs · 2016 · PMID 26938871 · validated civic_curation pubmed

A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.

· Lung Cancer · 2016 · PMID 26775591 · validated civic_curation pubmed

I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.

· Lung Cancer · 2015 · PMID 25736571 · validated civic_curation pubmed

Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.

· J Thorac Oncol · 2014 · PMID 25521405 · validated civic_curation pubmed

ROS1 rearrangements define a unique molecular class of lung cancers.

· J Clin Oncol · 2012 · PMID 22215748 · validated civic_curation pubmed

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.

· Clin Lung Cancer · 2015 · PMID 25922291 · validated civic_curation pubmed

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.

· Clin Cancer Res · 2006 · PMID 17085664 · validated civic_curation pubmed

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.

· J Thorac Oncol · 2015 · PMID 26565381 · validated civic_curation pubmed

Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.

· J Thorac Oncol · 2016 · PMID 27544060 · validated civic_curation pubmed

Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.

· Ann Oncol · 2017 · PMID 28950338 · validated civic_curation pubmed

Identification of a novel crizotinib-sensitive MET-ATXN7L1 gene fusion variant in lung adenocarcinoma by next generation sequencing.

· Ann Oncol · 2018 · PMID 30339198 · validated civic_curation pubmed

Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma.

· Cancer Res · 2013 · PMID 23786770 · validated civic_curation pubmed